This recombinant monoclonal antibody is designed as a research-grade biosimilar to Manfidokimab, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two cytokines central to type 2 inflammatory responses. Upon ligand binding, IL4R initiates signaling cascades that promote IgE class switching, mucus production, and recruitment of eosinophils. Dysregulated IL4R signaling plays a critical role in allergic diseases, atopic dermatitis, asthma, and certain fibrotic conditions, making it an important therapeutic target for type 2 inflammation-driven disorders.
Manfidokimab is a clinical-stage therapeutic antibody that blocks IL-4 and IL-13 signaling by binding to IL4R alpha, preventing downstream inflammatory cascades. This biosimilar provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immune responses, and exploring mechanisms of allergic and inflammatory diseases. It supports studies in immunology, dermatology, and respiratory research where IL4R modulation is of interest.
Email: support@cusabio.com
Distributors Worldwide